After-hours movers: HubSpot, DoorDash, DraftKings gain following EPS

After-Hours Stock Movers:

HubSpot (NYSE: HUBS) 12% HIGHER; reported Q4 EPS of $1.11, $0.34 better than the analyst estimate of $0.83. Revenue for the quarter came in at $469.7 million versus the consensus estimate of $446.25 million. HubSpot sees Q1 2023 EPS of $0.82-$0.84, versus the consensus of $0.59. HubSpot sees Q1 2023 revenue of $473-475 million, versus the consensus of $469.51 million. HubSpot sees FY2023 EPS of $4.24-$4.32, versus the consensus of $2.85. HubSpot sees FY2023 revenue of $2.05-2.06 billion, versus the consensus of $2.05 billion.

Otter Tail Corp. (NASDAQ: OTTR) 7% HIGHER; will replace UFP Industries in the S&P SmallCap 600

IVERIC bio, Inc. (Nasdaq: ISEE) 6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the companys New Drug Application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD). The NDA has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of August 19, 2023. The company also announced that, at this time, the FDA has not identified any potential review issues and the FDA is not currently planning to hold an Advisory Committee meeting for ACP.

DoorDash (NYSE: DASH) 6% HIGHER; reported Q4 EPS of ($1.65), $0.98 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $1.82 billion versus the consensus estimate of $1.77 billion. Currently expect Q1 Marketplace GOV to be in a range of $15.1 billion to $15.5 billion, with Q1 Adjusted EBITDA expected to be in a range of $120 million to $170 million. Currently expect 2023 Marketplace GOV to be in a range of $60.0 billion to $63.0 billion, with Adjusted EBITDA expected to be in a range of $500 million to $800 million.

DraftKings (NASDAQ: DKNG) 6% HIGHER; reported Q4 EPS of ($0.53), $0.08 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $855 million versus the consensus estimate of $798.23 million. DraftKings raises FY2023 revenue to $2.85-3.05 billion, versus the consensus of $2.95 billion.

Moderna, Inc. (NASDAQ: MRNA) 6% LOWER; announced interim results from its pivotal Phase 3 safety and immunogenicity trial of mRNA-1010 (P301), an mRNA-based seasonal influenza (flu) vaccine candidate, in adults. The Phase 3 randomized trial was designed to evaluate the safety and immunogenicity of mRNA-1010 in adults 18 years and older in the Southern Hemisphere. mRNA-1010 encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) to prevent influenza, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages.

UFP Industries Inc. (NASDAQ: UFPI) 3% LOWER; will replace LHC Group Inc. (NASDAW: LHCG) in the S&P MidCap 400

You May Also Be Interested In

• Scholar Rock updates apitegromab regulatory status in U.S., Europe, Japan
• Cingulate posts wider Q2 loss as SG&A spending more than doubles
• Pharvaris B.V. (PHVS) PT Raised to $75 at Citizens: Has Cash Runway Into 2028